SCHEMBL20536495

SCHEMBL20536495

Clc1ccc(COc2cc3nc(-c4ccncc4)[nH]c3c(Cl)c2Cl)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RHEB Q15382 5/20 0.69
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ LMNA P02545 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ PLK1 P53350 1/20 0.41
▸ GCGR P47871 5/20 0.40
▸ MAPK13 O15264 2/20 0.40
▸ MAPK12 P53778 2/20 0.40
▸ MAPK11 Q15759 2/20 0.40
▸ MAPK14 Q16539 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ PKM P14618 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ ROCK2 O75116 2/20 0.40
▸ GRK2 P25098 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20536755 0.77 RHEB (0.52) RHEBSMN1; SMN2LMNAMAPTHTT
SCHEMBL20535557 0.77 RHEB (0.46) RHEBSMN1; SMN2LMNAMAPTHTT
SCHEMBL20535604 0.75 RHEB (0.68) RHEBSMN1; SMN2LMNAMAPTHTT
SCHEMBL20536548 0.74 RHEB (0.62) RHEBSMN1; SMN2MAPTGCGRMAPK13
SCHEMBL23709600 0.72 RHEB (0.78) RHEB
SCHEMBL23709609 0.72 RHEB (0.51) RHEBSMN1; SMN2MAPTGCGRMAPK13
SCHEMBL23709602 0.67 RHEB (0.53) RHEBSMN1; SMN2NPC1RAB9A
SCHEMBL23709728 0.67 GAA (0.43) RHEBSMN1; SMN2LMNAMAPTHTT
SCHEMBL20535651 0.65 RHEB (0.70) RHEBSMN1; SMN2LMNAMAPTHTT
SCHEMBL23709935 0.65 RHEB (0.51) RHEBSMN1; SMN2LMNAMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2022-05-24 — — US disclosed
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2022-05-24 — — US disclosed
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2021-08-05 — — US disclosed
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2021-08-05 — — US disclosed
WO-2018191146-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. (US) 2018-10-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF RHEB, KRAS, NRAS RHEB 1/4885SMN1; SMN2 4200/4885LMNA 4243/4885
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof RHEB, GDI2, KRAS RHEB 1/4885SMN1; SMN2 2458/4885LMNA 2918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback